Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Introgen Files Advexin For Head And Neck Cancer In U.S., EU

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.
Advertisement

Related Content

FDA Refuses To File BLA For Cancer Gene Therapy
FDA Refuses To File BLA For Cancer Gene Therapy
Introgen Restructures To Ready For Advexin Approval Process
Introgen Restructures To Ready For Advexin Approval Process
Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients
Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients
Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS068013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel